Expanding Close-to-Me Infusion Services: Improving Access While Maintaining Safety (AVAHO 2026) - Oct 11, 2026 - Abstract #21; Pres time: Sep 11, 2026; 02:15 PM - 03:15 PM; "In Q1, the medications dispensed included intravenous immune globulin, infliximab, iron sucrose, ublituximab, ocrelizumab, natalizumab, risankizumab, methylprednisolone, vedolizumab, zoledronic acid, atezolizumab, degarelix, goserelin, pembrolizumab, and efgartigimod, and supportive care medications and pre-medications including clonidine, diphenhydramine, vitamin B-12, and normal saline. The new medications added in Q2 included denosumab, durvalumab, nivolumab-hyaluronidase, ocrelizumab-hyaluronidase, rituximab, romosozumab, and ustekinumab...Conclusions The CTM program expanded rapidly while achieving lower no-show rates than the main VA and successfully delivered complex therapies safely while reducing travel burden and costs. This staffing model offers a scalable, patient-centered approach to infusion care that could benefit Veterans nationwide."
Clinical • Hematological Disorders
|